Abstract
An immunotoxin containing an anti-CD30 monoclonal antibody (Ber-H2) and saporin, a ribosome-inactivating protein type 1, is described. It specifically inhibits protein synthesis by Hodgkin derived target cell lines with a very high efficiency (IC50 ranging from 5 x 10(-12) M to 5 x 10(-14) M, as saporin), while irrelevant immunotoxins do not. Present results suggest that this immunotoxin could be used for in vivo therapy as well as for ex vivo bone marrow purging in Hodgkin's disease and CD30+ lymphomas.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antibodies, Monoclonal / therapeutic use
-
Antigens, CD / immunology*
-
Antigens, Neoplasm / immunology*
-
Antineoplastic Agents, Phytogenic / therapeutic use
-
Cell Line
-
Drug Screening Assays, Antitumor
-
Hodgkin Disease / immunology
-
Hodgkin Disease / therapy*
-
Humans
-
Immunotoxins / therapeutic use*
-
Ki-1 Antigen
-
Lymphoma / therapy*
-
Mice
-
N-Glycosyl Hydrolases*
-
Plant Proteins / therapeutic use*
-
Ribosome Inactivating Proteins, Type 1
-
Ricin
-
Saporins
Substances
-
Antibodies, Monoclonal
-
Antigens, CD
-
Antigens, Neoplasm
-
Antineoplastic Agents, Phytogenic
-
Immunotoxins
-
Ki-1 Antigen
-
Plant Proteins
-
Ribosome Inactivating Proteins, Type 1
-
Ricin
-
N-Glycosyl Hydrolases
-
Saporins